Bayer: FDA approves vericiguat
(CercleFinance.com) - Bayer announced today that the US FDA has approved vericiguat (verquvo) as a treatment for patients with symptomatic chronic heart failure.
The approval is based on the results of the pivotal Phase III Victoria trial, published in the New England Journal of Medicine (NEJM) in March 2020 and follows the priority review granted by the FDA.
Vericiguat is being co-developed with MSD (a Merck & Co. trade name), which holds the commercial rights in the United States, while Bayer holds the exclusive commercial rights in the rest of the world.
Copyright (c) 2021 CercleFinance.com. All rights reserved.